Santa Monica’s Kite Pharma Inc., a cancer drug developer, this morning acknowledged a patient in one of its clinical trials died but says the death had nothing to do with its drug candidate, Investors.com reports. Kite’s stock fell at the end of last week after rumors a patient had died who was part of a trial for the company’s KTE-C19 drug.